Get the Stockscreener App
0.5875
2.90%
-0.0176
Vyne Therapeutics Inc stock is traded at $0.5875, with a volume of 31,674.
It is down -2.90% in the last 24 hours and up +2.34% over the past month.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.
See More
Previous Close:
$0.605
Open:
$0.5989
24h Volume:
31,674
Relative Volume:
0.01
Market Cap:
$19.55M
Revenue:
$570.00K
Net Income/Loss:
$-26.74M
P/E Ratio:
-0.9014
EPS:
-0.6517
Net Cash Flow:
$-33.12M
1W Performance:
+2.13%
1M Performance:
+2.34%
6M Performance:
+85.02%
1Y Performance:
-75.00%
1-Day Range:
$0.58
$0.5989
1-Week Range:
$0.5646
$0.608
52-Week Range:
$0.2805
$2.5699
Vyne Therapeutics Inc Stock (VYNE) Company Profile
Name
Vyne Therapeutics Inc
Sector
Industry
Phone
800-775-7936
Address
685 ROUTE 202/206 N., SUITE 301, BRIDGEWATER
Compare VYNE vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VYNE
Vyne Therapeutics Inc
|
0.5875 | 19.99M | 570.00K | -26.74M | -33.12M | -0.6517 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.25 | 126.21B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
775.00 | 82.64B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
748.22 | 47.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
317.01 | 44.15B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
295.96 | 35.08B | 4.98B | 69.60M | 525.67M | 0.5198 |
Vyne Therapeutics Inc Stock (VYNE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-31-25 | Downgrade | BTIG Research | Buy → Neutral |
| Nov-18-24 | Initiated | BTIG Research | Buy |
| Dec-06-21 | Resumed | H.C. Wainwright | Buy |
Vyne Therapeutics Inc Stock (VYNE) Latest News
VYNE Therapeutics (VYNE) to Release Quarterly Earnings on Thursday - Defense World
Aug Analyst Calls: Is Magnite Inc on track to beat earningsWeekly Profit Analysis & Verified Technical Signals - baoquankhu1.vn
Comparing Qualigen Therapeutics (NASDAQ:QLGN) and VYNE Therapeutics (NASDAQ:VYNE) - Defense World
Why is VYNE Therapeutics Inc. stock going upTrade Signal Summary & Proven Capital Preservation Methods - mfd.ru
Published on: 2026-02-14 10:12:41 - mfd.ru
VYNE Therapeutics Inc. (NASDAQ:VYNE) Sees Large Decline in Short Interest - Defense World
What analysts say about VYNE Therapeutics Inc. stockWeekly Stock Analysis & Accurate Intraday Trading Signals - mfd.ru
Can VYNE Therapeutics Inc. deliver consistent dividendsJuly 2025 Highlights & Detailed Earnings Play Alerts - mfd.ru
Published on: 2026-02-12 18:59:51 - mfd.ru
Can VYNE Therapeutics Inc. benefit from deglobalizationPortfolio Update Report & Capital Efficient Trading Techniques - mfd.ru
Published on: 2026-02-09 22:57:29 - baoquankhu1.vn
What analysts say about VYNE Therapeutics Inc stockEarnings Growth Summary & Smart Money Movement Tracker - baoquankhu1.vn
Portfolio Recap: Why is VYNE Therapeutics Inc stock going upBuy Signal & Reliable Momentum Entry Alerts - baoquankhu1.vn
Trade Report: What is the long term forecast for VYNE Therapeutics Inc stockInflation Watch & High Conviction Buy Zone Alerts - baoquankhu1.vn
Does MTCH stock have upside surprise potentialQuarterly Trade Report & Free Technical Pattern Based Buy Signals - baoquankhu1.vn
VYNE Therapeutics Amends Merger Terms with Yarrow Bioscience - TipRanks
VYNE Therapeutics Signs Amendment to Merger Agreement With Yarrow Bioscience - TradingView
Breakout Zone: Is VYNE Therapeutics Inc stock showing strong momentumTrade Performance Summary & Stock Market Timing Techniques - baoquankhu1.vn
How cyclical is VYNE Therapeutics Inc.’s revenue stream2025 Winners & Losers & Long-Term Growth Portfolio Plans - mfd.ru
Short Interest in VYNE Therapeutics Inc. (NASDAQ:VYNE) Decreases By 55.4% - Defense World
Support Test: Can SunCar Technology Group Inc. scale operations efficientlyMarket Movers & Verified Swing Trading Watchlists - baoquankhu1.vn
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Block Trades: Is VersaBank a potential multi baggerJuly 2025 Institutional & Technical Buy Zone Confirmations - baoquankhu1.vn
Is Sonoco Products Company exposed to currency risksMarket Growth Report & Verified Entry Point Signals - baoquankhu1.vn
Volume Summary: Is VYNE Therapeutics Inc stock showing strong momentumWeekly Risk Report & Real-Time Volume Trigger Notifications - baoquankhu1.vn
Analysis Recap: What is the long term forecast for VYNE Therapeutics Inc stockQuarterly Growth Report & Fast Entry High Yield Stock Tips - baoquankhu1.vn
Aug Opening: How does CCLDO correlate with NasdaqJuly 2025 Institutional & Technical Buy Zone Confirmations - baoquankhu1.vn
Weekly Earnings: Is SEALPRB stock a value trapJuly 2025 Gainers & Free Safe Capital Growth Stock Tips - baoquankhu1.vn
Aug EndMonth: Why is VYNE Therapeutics Inc stock going upWeekly Gains Report & Fast Momentum Entry Tips - baoquankhu1.vn
Is VYNE Therapeutics Inc. stock positioned well for digital economyJuly 2025 Pullbacks & Safe Entry Trade Reports - Улправда
Will VYNE Therapeutics Inc. stock remain a Wall Street favoriteJuly 2025 Trends & AI Enhanced Trading Alerts - Улправда
US Stocks Recap: Will VYNE Therapeutics Inc stock remain a Wall Street favoriteJuly 2025 Gainers & Free Safe Capital Growth Stock Tips - Bộ Nội Vụ
What insider trading reveals about VYNE Therapeutics Inc. stockJuly 2025 Chart Watch & Reliable Breakout Forecasts - ulpravda.ru
VYNE Therapeutics Inc. (NASDAQ:VYNE) Short Interest Down 18.2% in December - Defense World
VYNE Therapeutics Inc. (VYNE) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
VYNE SEC FilingsVyne Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Vyne Therapeutics shares surge on merger deal with Yarrow Bioscience - MSN
Why VYNE Therapeutics Inc. stock remains resilient2025 EndofYear Setup & Entry Point Confirmation Signals - Улправда
VYNE Therapeutics to merge with Yarrow Bioscience, secures $200M financing; shares up - MSN
Halper Sadeh LLC Encourages FOLD, VYNE, HTBK, FMNB Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire
Halper Sadeh LLC Encourages FOLD, VYNE, HTBK, FMNB Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire Inc.
How VYNE Therapeutics Inc. stock compares to industry benchmarksMarket Sentiment Review & AI Enhanced Market Trend Forecasts - Улправда
Should I hold or sell VYNE Therapeutics Inc. stock in 2025Market Activity Summary & High Conviction Trade Alerts - Улправда
Is VYNE Therapeutics Inc. stock resilient to inflation2025 Market Outlook & AI Based Buy and Sell Signals - Улправда
Shareholder Alert: The Ademi Firm investigates whether VYNE Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders - PR Newswire
Risk Analysis: Will VYNE Therapeutics Inc. stock benefit from automation2025 Buyback Activity & Real-Time Volume Surge Alerts - Улправда
3 Penny Stocks to Watch Now, 12/18/25 - TipRanks
VYNE Therapeutics to merge with Yarrow Bioscience in $200 million deal - Investing.com
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of VYNE Therapeutics Inc. (NASDAQ: VYNE) - PR Newswire
VYNE Therapeutics Inc. (VYNE) Stock: Soars 55.45% on Merger Announcement with Yarrow Bioscience - parameter.io
Roundup: Harbor BioMed Announces Collaboration and License Agreement with Bristol Myers, Squibb, VYNE Therapeutics Enters Merger Agreement with Yarrow Bioscience - PharmExec.com
Vyne Therapeutics Inc Stock (VYNE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):